Behind the Drug Discounts: 340B, Medicare Negotiation, and Transparency

Why It Matters

Duplicate discounts could siphon billions from Medicare savings and strain 340B providers, making transparency reforms essential for fiscal integrity and patient access.

Key Takeaways

• MFP rebates now flow daily, adding operational complexity.
• 340B and MFP discounts often overlap, risking duplicate rebates.
• Manufacturers face new liability, needing rapid data exchange within 14 days.
• Good‑faith inquiries resolved 70% of time, averaging ten days.
• Transparency gaps could waste billions, prompting regulatory scrutiny.

Summary

The webinar examined how the Inflation Reduction Act’s Medicare drug‑price negotiation program—delivering Maximum Fair Prices (MFPs) for ten high‑spend Part D drugs—intersects with the longstanding 340B discount system. Panelists explained the operational pipeline: claims adjudicated by plans, rebates routed through a government‑appointed transaction facilitator (MTF), then validated and duplicated by data‑management firms to flag overlapping discounts. The process now averages 21 days from service to pharmacy payment, a speed far quicker than earlier estimates.

Key findings highlighted the shift from quarterly manufacturer rebates to near‑daily MFP transactions, creating a cascade of seven to fifteen data exchanges per rebate. This high‑frequency flow generated numerous reversals and adjustments, and the differing cadence of 340B discounts amplified the risk of duplicate payments. Manufacturers, previously accustomed to chargebacks to wholesalers, must now track both MFP and 340B modifiers on each claim.

Katherine Richardson illustrated the complexity with a diagram likening the system to a train on mismatched tracks, while data from IQVIA showed over 900 pharmacies filing good‑faith inquiries—about 70 % resolved within ten days. These inquiries largely centered on whether a 340B discount should be applied alongside an MFP rebate, underscoring the confusion at the pharmacy level.

The collision of the two programs threatens billions of dollars in duplicate discounts, eroding the intended savings for Medicare and for safety‑net providers. Greater transparency, standardized claim tagging, and possibly a centralized oversight mechanism are needed to safeguard both programs and to preserve incentives for pharmaceutical innovation.

Original Description

How do the Medicare Drug Price Negotiation and 340B programs intersect? Rory Martin of IQVIA and Katheryne Richardson of Second Sight Solutions examine insights on Medicare drug pricing, 340B transparency gaps, duplicate discounts, and evolving policy.

---

Visit Health Affairs: http://www.healthaffairs.org

Subscribe and Listen to our Podcasts: https://www.healthaffairs.org/podcasts

Sign up for our free Newsletters: https://www.healthaffairs.org/newsletters